[{"id":"c57218fe-9186-4e3a-b510-e014a45f68cf","acronym":"Amaretto","url":"https://clinicaltrials.gov/study/NCT04981691","created_at":"2021-07-29T14:53:07.374Z","updated_at":"2024-07-02T16:36:24.273Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04981691 - Amaretto","lead_sponsor":"Ruijin Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • UCLM802"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 01/09/2022","primary_completion_date":" 01/09/2022","study_txt":" Completion: 07/09/2022","study_completion_date":" 07/09/2022","last_update_posted":"2021-09-17"},{"id":"864e20df-a59c-41cd-b490-615021eb2ec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03545815","created_at":"2021-01-18T17:27:27.742Z","updated_at":"2024-07-02T16:36:42.187Z","phase":"Phase 1","brief_title":"Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.","source_id_and_acronym":"NCT03545815","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC008t • MPTK-CAR-T cells • MSLN CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2020-08-10"},{"id":"38a358aa-4637-4d62-88fe-5f1f4ce41f8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03692637","created_at":"2021-01-18T18:05:54.027Z","updated_at":"2024-07-02T16:37:03.340Z","phase":"Phase 1","brief_title":"Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03692637","lead_sponsor":"Allife Medical Science and Technology Co., Ltd.","biomarkers":" PD-L1 • PD-1 • MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["PD-L1 • PD-1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN CAR-T • anti-Mesothelin CAR NK Cells"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-01-31"},{"id":"40516fe7-06f1-4482-9d62-ee5ed2208d4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02930993","created_at":"2021-01-18T14:23:37.310Z","updated_at":"2024-07-02T16:37:28.541Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors","source_id_and_acronym":"NCT02930993","lead_sponsor":"China Meitan General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2016-10-12"}]